Immunotherapy is a treatment that works by boosting the immune system in order for our body to fight cancer better, but it does not work for every patient. Based on the Phoenix Biomedical Campus and using technology licensed from ASU, OncoMyx Therapeutics has discovered a way to use a virus that infects rabbits but does NOT hurt people to make immune therapies even more effective and is working to develop new medicines and combinations of medicines that can save more lives.
OncoMyx Therapeutics is advancing multi-armed, systemic immunotherapies with the potential to be broadly effective in treating solid tumors and heme cancers. Successful immuno-oncology cancer treatment generally requires combination therapy, and OncoMyx’s myxoma platform is designed to deliver multiple cancer-killing payloads in one therapeutic and orchestrate an immune response capable of treating a wide range of cancers. OncoMyx has assembled a top immuno-oncology team to develop next generation immunotherapies that can have the greatest therapeutic benefit for more cancer patients. The company’s myxoma virus platform is poised to be a best-in-class oncolytic virus approach and was developed based on breakthrough research from Dr. Grant McFadden’s lab that was exclusively licensed from Arizona State University.
Throughout 2022, Sonoran Living fans will have the opportunity to learn about the Arizona life science innovators who are working to make life better for all of us. To learn more about Arizona Health Innovations, visit AZBio.org/AZAdvances.
Sonoran Living Health Innovation Spotlights and Segments are produced by ABC15 and are paid for by AZBio.